J Endocrinol Metab

Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access

Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc

Journal website http://www.jofem.org

Original Article

Volume 4, Number 3, June 2014, pages 56-63

Hormonal Contraceptive Use After Venous Thrombosis: Practice From 1999 to 2004

**Table 1.** General Characteristics
	Women who stopped	Women who changed	Women who continued
^aData on BMI, smoking and family history were available in 665, 682 and 556 women, respectively. ^bUser of lynestrenol, a first generation progestagen.
Age, mean (range), years	36 (18 - 49)	34 (20 - 48)	36 (18 - 49)
BMI^a
> 30%	126 (76)	11 (7)	29 (17)
25-30%	156 (75)	20 (10)	33 (16)
< 25%	210 (73)	29 (10)	50 (17)
Smoking^a
Current (%)	213 (76)	22 (8)	45 (16)
Ever (%)	89 (77)	10 (9)	17 (15)
Never (%)	203 (71)	30 (11)	52 (18)
Positive family history^a
Yes (%)	115 (82)	7 (5)	18 (13)
No (%)	300 (72)	40 (10)	75 (18)
Contraception
Combined oral contraceptives (%)	508 (75)	60 (9)	114 (17)
First generation (%)	32 (86)	1 (3)	4 (11)
Second generation (%)	212 (76)	13 (5)	53 (19)
Third generation (%)	213 (74)	37 (13)	38 (13)
Cyproterone acetate (%)	45 (64)	8 (11)	17 (24)
Drospirenone (%)	6 (67)	1 (11)	2 (22)
Progestagen-only contraceptives (%)	12 (60)	3 (15)	5 (25)
Oral progestagen-only^b (%)	0 (0)	1 (100)	0 (0)
Intra-uterine device (%)	0 (0)	0 (0)	1 (100)
Implanon (%)	1 (100)	0 (0)	0 (0)
Injectables (%)	11 (65)	2 (12)	4 (24)
Unknown (%)	1 (100)	0 (0)	0 (0)

Table 1. General Characteristics

Women who stopped

Women who changed

Women who continued

N = 521

N = 63

N = 119

^aData on BMI, smoking and family history were available in 665, 682 and 556 women, respectively. ^bUser of lynestrenol, a first generation progestagen.

Age, mean (range), years

36 (18 - 49)

34 (20 - 48)

36 (18 - 49)

BMI^a

> 30%

126 (76)

11 (7)

29 (17)

25-30%

156 (75)

20 (10)

33 (16)

< 25%

210 (73)

29 (10)

50 (17)

Smoking^a

Current (%)

213 (76)

22 (8)

45 (16)

Ever (%)

89 (77)

10 (9)

17 (15)

Never (%)

203 (71)

30 (11)

52 (18)

Positive family history^a

Yes (%)

115 (82)

7 (5)

18 (13)

No (%)

300 (72)

40 (10)

75 (18)

Contraception

Combined oral contraceptives (%)

508 (75)

60 (9)

114 (17)

First generation (%)

32 (86)

1 (3)

4 (11)

Second generation (%)

212 (76)

13 (5)

53 (19)

Third generation (%)

213 (74)

37 (13)

38 (13)

Cyproterone acetate (%)

45 (64)

8 (11)

17 (24)

Drospirenone (%)

6 (67)

1 (11)

2 (22)

Progestagen-only contraceptives (%)

12 (60)

3 (15)

5 (25)

Oral progestagen-only^b (%)

0 (0)

1 (100)

0 (0)

Intra-uterine device (%)

0 (0)

1 (100)

Implanon (%)

1 (100)

0 (0)

Injectables (%)

11 (65)

2 (12)

4 (24)

Unknown (%)

1 (100)

0 (0)

**Table 2.** Pattern of Changes After an Hormonal Contraceptive-Associated Venous Thrombosis Event
Contraceptive at event	Contraceptive method after venous thrombosis
First gen: first generation progestagen; second gen: second generation progestagen; third gen: third generation progestagen; CPA: cyproterone acetate; DRSP: drospirenone; POP: progestagen-only pills; IUD: intra-uterine device.
Combined oral contraceptives
First gen (%)	-	-	-	-	-	1 (100)	-	-
Second gen (%)	-	3 (23)	1 (8)	-	-	7 (54)	-	2 (15)
Third gen (%)	-	20 (54)	-	-	2 (5)	10 (27)	2 (5)	3 (8)
CPA (%)	-	3 (38)	1 (13)	1 (13)	-	3 (38)	-	-
Drospirenone (%)	-	-	-	-	-	1 (100)	-	-
Progestagen-only contraceptives
POP (%)	-	-	-	-	-	1 (100)	-	-
Injectables (%)	-	-	-	-	-	2 (100)	-	-
Total	0	26 (41)	2 (3)	1 (2)	2 (3)	25 (40)	2 (3)	5 (8)

Table 2. Pattern of Changes After an Hormonal Contraceptive-Associated Venous Thrombosis Event

Contraceptive at event

Contraceptive method after venous thrombosis

First gen

Second gen

Third gen

DRSP

POP

IUD

Implanon

Injectables

First gen: first generation progestagen; second gen: second generation progestagen; third gen: third generation progestagen; CPA: cyproterone acetate; DRSP: drospirenone; POP: progestagen-only pills; IUD: intra-uterine device.

Combined oral contraceptives

First gen (%)

1 (100)

Second gen (%)

3 (23)

1 (8)

7 (54)

2 (15)

Third gen (%)

20 (54)

2 (5)

10 (27)

2 (5)

3 (8)

CPA (%)

3 (38)

1 (13)

3 (38)

Drospirenone (%)

1 (100)

Progestagen-only contraceptives

POP (%)

1 (100)

Injectables (%)

2 (100)

Total

26 (41)

2 (3)

1 (2)

2 (3)

25 (40)

2 (3)

5 (8)

**Table 3.** Exposure to Acquired Risk Factors in Women Who Stop, Continue or Change Their Hormonal Contraceptive Preparation
	Stop	Risk difference	Change	Risk difference	Continue	Risk difference
^aOf 17 women, no data were available on exposure to an acquired risk factor.
Acquired risk factor^a
None (%)	267 (77)	Reference	31 (9)	Reference	51 (15)	Reference
Any (%)	240 (71)	-5 (-12 to 1)	31 (9)	0 (-4 to 5)	66 (20)	5 (-1 to 11)
Surgery (%)	48 (58)	-19 (-30 to -8)	7 (8)	0 (-6 to 8)	28 (34)	19 (9 to 30)
Immobilization (%)	70 (70)	-7 (-17 to 3)	14 (14)	5 (-1 to 14)	16 (16)	1 (-6 to 11)
Plaster cast (%)	19 (59)	-17 (-35 to -1)	3 (9)	1 (-7 to 16)	10 (31)	17 (3 to 34)
Injury (%)	73 (74)	-3 (-13 to 6)	8 (8)	-1 (-6 to 7)	18 (18)	4 (-4 to 13)
Travel (%)	108 (82)	6 (-3 to 13)	8 (6)	-3 (-7 to 3)	15 (11)	-3 (-9 to 4)

Table 3. Exposure to Acquired Risk Factors in Women Who Stop, Continue or Change Their Hormonal Contraceptive Preparation

Stop

Risk difference

Change

Risk difference

Continue

Risk difference

N = 521

95% CI

N = 63

95% CI

N = 119

95% CI

^aOf 17 women, no data were available on exposure to an acquired risk factor.

Acquired risk factor^a

None (%)

267 (77)

Reference

31 (9)

Reference

51 (15)

Reference

Any (%)

240 (71)

-5 (-12 to 1)

31 (9)

0 (-4 to 5)

66 (20)

5 (-1 to 11)

Surgery (%)

48 (58)

-19 (-30 to -8)

7 (8)

0 (-6 to 8)

28 (34)

19 (9 to 30)

Immobilization (%)

70 (70)

-7 (-17 to 3)

14 (14)

5 (-1 to 14)

16 (16)

1 (-6 to 11)

Plaster cast (%)

19 (59)

-17 (-35 to -1)

3 (9)

1 (-7 to 16)

10 (31)

17 (3 to 34)

Injury (%)

73 (74)

-3 (-13 to 6)

8 (8)

-1 (-6 to 7)

18 (18)

4 (-4 to 13)

Travel (%)

108 (82)

6 (-3 to 13)

8 (6)

-3 (-7 to 3)

15 (11)

-3 (-9 to 4)

**Table 4.** Results of a Subgroup Analysis in 414 Women
Variable	Stop	Risk difference	Change	Risk difference	Continue	Risk difference
Advice to stop
Do not know	3 (50)		1 (17)		2 (33)
No	23 (34)	Reference	9 (13)	Reference	35 (52)	Reference
Yes	284 (83)	49 (36 to 60)	27 (8)	-6 (-16 to 2)	30 (9)	-43 (-55 to -31)

Table 4. Results of a Subgroup Analysis in 414 Women

Variable

Stop

Risk difference

Change

Risk difference

Continue

Risk difference

N = 311

95% CI

N = 37

95% CI

N = 67

95% CI

Advice to stop

Do not know

3 (50)

1 (17)

2 (33)

23 (34)

Reference

9 (13)

Reference

35 (52)

Reference

Yes

284 (83)

49 (36 to 60)

27 (8)

-6 (-16 to 2)

30 (9)

-43 (-55 to -31)